Flossie buys XON 25.93: FIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell Th ...
The companyâs collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating rare and serious skin and connective tissue diseases for which there are no currently approved . ... ...
28 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home